Pharma major Dr Reddy's Laboratories Ltd said it has launched its generic Methylprednisolone Sodium Succinate for injection, indicated for various conditions including arthritis, blood disorders and severe allergic reactions, in the US market.

The injection is the generic equivalent of SOLU-MEDROL and has been approved by the US Food and Drug Administration (USFDA), the company said in a regulatory filing.

Click for more articles on USFDA

Dr Reddy's Methylprednisolone Sodium Succinate for Injection is supplied in 40 mg/vial, 125 mg/vial single-dose vials, each carton containing 25 vials and 500 mg and 1 gm multi-dose vial each carton containing 1 vial, it added.

Citing IQVIA Health data, the company said the SOLU-MEDROL brand and its generic versions had US sales of approximately USD 144 million for the most recent twelve months ended February 2022.

Certain Products recalled due to Microbial Contamination

USFDA approves Cell Therapy for earlier lymphoma

Drug Recall: IDArubicin Hydrochloride Injection recalled due to this reason

USFDA gives 13 observations to Lupin

Govt further extends timeline to apply for slots under PLI scheme

CDSCO panel gives nod to Roche for Anticancer Drug Entrectinib Capsules

Nutraceuticals Regulations 2022 to encourage Pharma Industry

Telangana to fill posts of 18 Drug Inspectors, 442 Pharmacists and 15 junior Analysts

NPPA updated price lists: Download

Latest Notifications regarding Pharmaceuticals
https://thehealthmaster.com/2022/04/06/dr-reddys-launches-generic-methylprednisolone-sodium-succinate-for-injection/